Education

Ph.D. in Pathology & Cell Biology, School of Medicine, University of Barcelona, Spain, 2012

Current position

Assistant Professor, Mount Sinai School of Medicine, Pathology Department, New York, USA, 2012

Publications

1. Carceles-Cordon, M., Rodriguez-Fernandez, I., Rodriguez-Bravo, V., Cordon-Cardo, C. and Domingo-Domenech, J. (2016). In vivo bioluminescence imaging of luciferase-labeled cancer cells. Bio-protocol 6(6): e1762.
   
2. Tovar, V., Cornella, H., Moeini, A., Vidal, S., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., Martinez-Quetglas, I., Lozano, J. J., Desbois-Mouthon, C., Solé, M., Domingo-Domenech, J., Villanueva, A. and Llovet, J. M. (2015). Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut.
   
3. Williams, E. S., Rodriquez-Bravo, V., Chippada-Venkata, U., De Ia Iglesia-Vicente, J., Gong, Y., Galsky, M., Oh, W., Cordon-Cardo, C. and Domingo-Domenech, J. (2015). Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp(105): 53182.
   
4. Vidal, S. J., Rodriguez-Bravo, V., Quinn, S. A., Rodriguez-Barrueco, R., Lujambio, A., Williams, E., Sun, X., de la Iglesia-Vicente, J., Lee, A., Readhead, B., Chen, X., Galsky, M., Esteve, B., Petrylak, D. P., Dudley, J. T., Rabadan, R., Silva, J. M., Hoshida, Y., Lowe, S. W., Cordon-Cardo, C. and Domingo-Domenech, J. (2015). A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27(2): 223-239.
   
5. Vidal, S. J., Quinn, S. A., de la Iglesia-Vicente, J., Bonal, D. M., Rodriguez-Bravo, V., Firpo-Betancourt, A., Cordon-Cardo, C. and Domingo-Domenech, J. (2014). Isolation of cancer stem cells from human prostate cancer samples. J Vis Exp(85).
   
6. Vidal, S. J., Rodriguez-Bravo, V., Galsky, M., Cordon-Cardo, C. and Domingo-Domenech, J. (2014). Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 33(36): 4451-4463.
   
7. Galsky, M. D. and Domingo-Domenech, J. (2013). Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clin Adv Hematol Oncol 11(2): 86-92.
   
8. Jia, A. Y., Castillo-Martin, M., Domingo-Domenech, J., Bonal, D. M., Sánchez-Carbayo, M., Silva, J. M. and Cordon-Cardo, C. (2013). A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol 182(4): 1171-1179.
   
9. Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., Petrylak, D. P., Benson, M. C., Silva, J. M. and Cordon-Cardo, C. (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22(3): 373-388.
   
10. Shen, T. H., Gladoun, N., Castillo-Martin, M., Bonal, D., Domingo-Domenech, J., Charytonowicz, D. and Cordon-Cardo, C. (2012). A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. PLoS One 7(4): e35243.
    
11. Wosnitzer, M. S., Domingo-Domenech, J., Castillo-Martin, M., Ritch, C., Mansukhani, M., Petrylack, D. P., Benson, M. C., McKiernan, J. M. and Cordon-Cardo, C. (2011). Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol 186(5): 2094-2100.
    
12. Karni-Schmidt, O.*, Castillo-Martin, M.*, Shen, T. H., Gladoun, N., Domingo-Domenech, J., Sanchez-Carbayo, M., Li, Y., Lowe, S., Prives, C. and Cordon-Cardo, C. (2011). Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 178(3): 1350-1360.
    
13. Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. and Cordon-Cardo, C. (2010). Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28(4): 401-408.
    
14. Conill, C., Valduvieco, I., Domingo-Domènech, J., Arguis, P., Vidal-Sicart, S. and Vilalta, A. (2009). Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clin Transl Oncol 11(10): 688-693.
    
15. Domingo-Domenech, J., Pippa, R., Tapia, M., Gascon, P., Bachs, O. and Bosch, M. (2008). Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112(1): 53-62.
    
16. Grau, J. J., Caballero, M., Monzo, M., Munoz-Garcia, C., Domingo-Domenech, J., Navarro, A., Conill, C., Campayo, M. and Bombi, J. A. (2008). Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 98(2): 130-134.
    
17. Domingo-Domenech, J., Fernandez, P. L., Filella, X., Martinez-Fernandez, A., Molina, R., Fernandez, E., Alcaraz, A., Codony, J., Gascon, P. and Mellado, B. (2008). Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 19(2): 269-275.
    
18. Temozolomida en pacientes con metástasis cerebrales de melanoma tratados con irradiación holocraneal. Conill Llobet, C., Valduvieco Ruiz, I., Vargas Rugeles y, M., Domingo-Doménech, J. (2008). Capítulo 5. Evidencia vs Experiencia – Temozolomida – Tumores cerebrales. Book chapter (Spanish).
    
19. Caballero, M., Grau, J. J., Blanch, J. L., Domingo-Domenech, J., Auge, J. M., Jimenez, W. and Bernal-Sprekelsen, M. (2007). Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 133(11): 1143-1148.
    
20. Domingo-Domenech, J., Castel, T., Auge, J. M., Garcia-Albeniz, X. A., Conill, C., Puig, S., Vilella, R., Matas, J., Malvehy, J., Gascon, P., Mellado, B. and Molina, R. (2007). Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol 28(5): 264-272.
    
21. Conill, C., Jorcano, S., Domingo-Domenech, J., Marruecos, J., Vilella, R., Malvehy, J., Puig, S., Sanchez, M., Gallego, R. and Castel, T. (2007). Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 17(5): 304-309.
    
22. Conill, C., Marruecos, J., Verger, E., Berenguer, J., Lomeña, F., Domingo-Domènech, J., Grau, J. J. and Casas, F. (2007). Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer. Clin Transl Oncol 9(3): 172-176.
    
23. Conill, C., Gimferrer, J. M., Marruecos, J., Domingo-Domènech, J., Vilella, R., Catalán, M., Malvehy, J., Puig, S. and Castel, T. (2007). Clinical outcome after surgical resection of lung metastases from melanoma. Clin Transl Oncol 9(1): 48-52.
    
24. Domingo-Domenech, J., Oliva, C., Rovira, A., Codony-Servat, J., Bosch, M., Filella, X., Montagut, C., Tapia, M., Campas, C., Dang, L., Rolfe, M., Ross, J. S., Gascon, P., Albanell, J. and Mellado, B. (2006). Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12(18): 5578-5586.
    
25. Grau, J. J., Palmero, R., Marmol, M., Domingo-Domenech, J., Monzó, M., Fuster, J., Vidal, O., Fondevila, C. and Garcia-Valdecasas, J. C. (2006). Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy. World J Surg Oncol 4: 53.
    
26. Conill, C., Jorcano, S., Domingo-Domènech, J., Gallego, R., Malvehy, J., Puig, S., Sanchez, M., Vilella, R. and Castel, T. (2006). Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. Clin Transl Oncol 8(4): 266-270.
    
27. Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domènech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascón, P., Rovira, A. and Albanell, J. (2006). Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5(3): 665-675.
    
28. Domingo-Domènech, J., Mellado, B., Ferrer, B., Truan, D., Codony-Servat, J., Sauleda, S., Alcover, J., Campo, E., Gascon, P., Rovira, A., Ross, J. S., Fernandez, P. L. and Albanell, J. (2005). Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93(11): 1285-1294.
    
29. Domingo-Domènech, J., Molina, R., Castel, T., Montagut, C., Puig, S., Conill, C., Martí, R., Vera, M., Auge, J. M., Malvehy, J., Grau, J. J., Gascón, P. and Mellado, B. (2005). Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR. Oncology 68(4-6): 341-349.
    
30. Molina, R., Auge, J. M., Filella, X., Viñolas, N., Alicarte, J., Domingo, J. M. and Ballesta, J. C. (2005). Pro-gastrinreleasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Antican Res 25(3A):1773-1778.
    
31. Grau, J. J., Domingo-Domènech, J., Morente, V., Pera, M., Garcia-Valdecasas, J. C., Fuster, J., Bombi, A., Mellado, B., Albanell, J. and Gascón, P. (2004). Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology 66(3): 226-233.
    
32. Manual de trasplante hematopoyetico. Enric Carreras y Josep Domingo-Domenech. (2004). Capitulo 8. Book chapter (Spanish).
    
33. Mellado, B., Del Carmen Vela, M., Colomer, D., Gutierrez, L., Castel, T., Quinto, L., Fontanillas, M., Reguart, N., Domingo-Domènech, J. M., Montagut, C., Estapé, J. and Gascón, P. (2002). Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 20(19): 4032-4039.
    
34. Grau, J. J., Domingo, J., Blanch, J. L., Verger, E., Castro, V., Nadal, A., Alós, L. and Estapé, J. (2002). Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology 63(4): 338-345.
    
35. Domingo-Domènech, J., Fernandez, J., Lopez-Guillermo, A. and Miquel, R. (2002). [Fulminant hepatic failure as form of presentation of a peripheral T cell lymphoma]. Med Clin (Barc) 119(18): 715-716.